Sequent Scientific Limited
Viyash Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides finished dosage formulation in therapeutic areas, such as nutrition, pain management, parasite control, antibiotics, and gut health for livestock, poultry, and companion animals. It also offers analytical services; and VET formulation services. The company was formerly known as Sequent Scientific Limited and changed its name to Viyash Scientific Limited in January 2026. The company was incorporated in 1985 and is headquartered in Hyderabad, India. Viyash Scientific Limited operates as a subsidiary of CA Harbor Investments.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Strong short-term liquidity β current ratio of 21.11x
Concerns1
- Low return on equity of 0.1%
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ178.00 Cr | β | βΉ16.00 Cr | β | β | 1.4% | 5.3% | 1500.0% |
| Mar 2024 | βΉ169.00 Cr | β | βΉ1.00 Cr | β | β | 0.1% | -24.2% | -116.7% |
| Mar 2023 | βΉ223.00 Cr | β | βΉ-6.00 | β | β | -0.6% | 1.4% | -140.0% |
| Mar 2022 | βΉ220.00 Cr | β | βΉ15.00 Cr | β | β | 1.4% | -17.0% | -53.1% |
| Mar 2021 | βΉ265.00 Cr | β | βΉ32.00 Cr | β | β | 3.1% | 16.7% | 52.4% |
| Mar 2020 | βΉ227.00 Cr | β | βΉ21.00 Cr | β | β | 2.4% | 36.7% | 162.5% |
| Mar 2019 | βΉ166.00 Cr | β | βΉ8.00 Cr | β | β | 0.9% | 56.6% | -98.0% |
| Mar 2018 | βΉ106.00 Cr | β | βΉ406.00 Cr | β | β | 42.8% | 16.5% | β |
| Mar 2017 | βΉ91.00 Cr | β | βΉ0.00 | β | β | 0.0% | -77.0% | -100.0% |
| Mar 2016 | βΉ395.00 Cr | β | βΉ10.00 Cr | β | β | 0.8% | 2.9% | -75.6% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 154 |
| Total Expenses | 166 |
| EBIT / Operating Profit | -12 |
| OPM % | -8% |
| Other Income | 44 |
| Finance Costs | 4 |
| Depreciation & Amortisation | 9 |
| Profit Before Tax | 19 |
| Tax % | - |
| Net Profit / PAT | 13 |
| EPS (βΉ) | 0.53 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Sequent Scientific Limitedthis co. | βΉ8.29 K Cr | βΉ178.00 Cr | 531.00 | 4.05 | 633.46 | 5.3% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |